Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) (DAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01822951
Recruitment Status : Withdrawn
First Posted : April 4, 2013
Last Update Posted : October 26, 2015
Sponsor:
Information provided by (Responsible Party):
Ever Neuro Pharma GmbH

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : September 2016
Estimated Study Completion Date : December 2016
Publications:
Xiao S, Yan H, Yao P. Efficacy of Cerebrolysin in patients with Alzheimer's disease. Clin. Drug Invest. 2000; 19:43-53.